Novonesis Novozymes B Stock Price Declines Amid Market Volatility

Novonesis Novozymes B, a Danish company specializing in industrial enzymes and microorganisms, has experienced a decline in its stock price in the current market. This trend contrasts with the overall performance of the Danish stock market, where the company’s shares have risen despite a significant drop.

According to analysts at DNB Carnegie, the target price for Novonesis has been raised to 505 Danish kronor. The analysts have reaffirmed their “buy” recommendation for the company.

The company’s prospects are also influenced by the growing demand for probiotics in animal feed. Market projections indicate a significant expansion of this market in the coming years.

Key Developments:

• Novonesis Novozymes B’s stock price has declined in the current market
• DNB Carnegie analysts have raised the target price to 505 Danish kronor
• Analysts have reaffirmed their “buy” recommendation for the company
• Growing demand for probiotics in animal feed is expected to drive market expansion